The once powerful pharmaceutical lobby is in over its head.
For years, the industry was successful in fighting off efforts to provide senior citizens with low-cost drugs. But a presidential election year coupled with a close race in the House of Representatives has pushed the issue to the fore, and the drug makers’ lobby is in disarray.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]